Health IT Promises More Timely Drug Information - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Health IT Promises More Timely Drug Information
FDA modernizes information systems, expands access to drug safety and use information.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 30-38

Participation and privacy

OMOP's agenda reflects strong industry interest in shaping and supporting Sentinel policies and operations. Unfortunately, this coalition is the primary way for manufacturers to influence the project. There are no industry representatives on the Sentinel planning board, and OMOP is not an official participant in the program, largely due to concerns among some stakeholders that manufacturer involvement could rtaint the validity of results. Pharmaceutical companies may feel compelled to build independent versions of Sentinel if excluded from the FDA project and denied access to Sentinel data. Woodcock noted that the mini-Sentinel system can't yet support third-party postmarketing analysis, and that FDA will have to deal with industry access once the "industrial strength Sentinel" emerges.

Ensuring the privacy and security of patient health records is also key to shaping the Sentinel program. One core advantage of the distributed data model is that FDA avoids building its own mega-database and instead leaves individual patient health information with the insurance company or healthcare system that holds the records. That data source evaluates the information, transmits summaries to Sentinel, and confirms a specific diagnosis or report if needed. It remains to be seen, however, how well FDA can assess safety signals with this arrangement. FDA staffers will be able to access de-identified data from Medicare and perform their own analysis, but it still may be hard to confirm whether a safety issue is real based on such limited information.

Another tricky issue for industry and policymakers is the timing of public disclosure of safety information. "The biggest risk to Sentinel is false positives," comments Marcus Wilson, president of HealthCore, the data analysis subsidiary of WellPoint. Information that is released too early increases the possibility that a report may be wrong or incomplete and, thus, raises unnecessary alarm. But delaying communication on an emerging safety issue may result in patient harm and expose program participants to "failure to warn" liability charges. At the Sentinel workshop, attorney Kristen Rosati encouraged FDA to develop model procedures for when, how, and to whom to report drug safety findings to set a policy that can be applied in court.

FDA also has to determine how it will use Sentinel findings in regulatory decisions. Confirmation of safety signals could result in changes in a product's labeling, agency alerts to healthcare professionals, and public warnings about appropriate drug use. Despite concerns about the completeness, objectivity and timing of drug-safety reports, "What we're going to get is going to be better that what we have right now," Woodcock predicted.

Broader system

Sentinel's prime purpose is to serve FDA's regulatory mission, but it eventually may be part of a multipurpose network that provides safety information to multiple public and private users, said McClellan. For example, the program can support the International Serious Adverse Events Consortium's search for genetic links to drug-induced safety problems. In the longterm, Sentinel may be part of a larger health information system that provides data for outcomes studies, comparative-effectiveness research (CER), and health-system quality reporting. Manufacturers support building such a network, said Paul Stang of Johnson & Johnson, but building one requires more investment.

Carolyn Clancy, director of the Agency for Healthcare Research and Quality, concluded the workshop by describing a range of initiatives to improve patient registries and to build distributed data research networks that can answer queries related to the effectiveness and safety of medical services and products. An overarching goal is to identify synergies between postmarketing surveillance and CER and to provide incentives for healthcare providers to participate in eHealth activities.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here